Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 6/20 | 0.51 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | TYK2 | P29597 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2560113 | 0.85 | LMNA (0.48) | CYP1A2HPGDSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL2563131 | 0.85 | CYP1A2 (0.50) | P2RX7CYP1A2HPGDALDH1A1KMT2A | |
| SCHEMBL2566570 | 0.83 | HPGD (0.59) | P2RX7CYP1A2HPGDALDH1A1LMNA | |
| SCHEMBL2565499 | 0.82 | NPC1 (0.58) | CYP1A2HPGDSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL2562980 | 0.81 | CYP1A2 (0.70) | P2RX7CYP1A2HPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL6424788 | 0.78 | HPGD (0.46) | CYP1A2HPGDSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL2563237 | 0.78 | HDAC1 (0.53) | P2RX7CYP1A2TYK2HPGDLMNA | |
| SCHEMBL2575468 | 0.78 | P2RX7 (0.51) | P2RX7P2RY12TYK2HPGDSMN1; SMN2 | |
| SCHEMBL2560127 | 0.74 | HPGD (0.55) | HPGDALDH1A1KMT2A | |
| SCHEMBL2566508 | 0.74 | HPGD (0.61) | HPGDLMNAHTTKMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399416-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-11-02 | — | — | EP | claimed |
| EP-1399416-A4 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-12-28 | — | — | EP | claimed |
| US-6852882-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-08 | — | — | US | claimed |
| US-20040157916-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2004-08-12 | — | — | US | claimed |
| EP-1399416-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2004-03-24 | — | — | EP | claimed |
| WO-2002098901-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-12-12 | — | — | WO | claimed |
| EP-1399416-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-11-02 | — | — | EP | disclosed |
| EP-1399416-A4 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-12-28 | — | — | EP | disclosed |
| US-6852882-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040157916-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2004-08-12 | — | — | US | disclosed |
| EP-1399416-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2004-03-24 | — | — | EP | disclosed |
| WO-2002098901-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157916-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | P2RX7 3139/4885P2RY12 3881/4885CYP1A2 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.